Bengaluru/Brussels | The European Union on Monday (Tuesday AEDT) approved the use of Novavax’s COVID-19 vaccine in people 18 years and older, giving a boost to the US biotech after long delays and paving the way for a fifth shot in the EU as the omicron variant spreads.
Data from two large studies showed the vaccine had an efficacy rate of about 90 per cent, the European Medicines Agency (EMA) said.
